 Once the MTD has been determined for each cohort, we will recruit an additional 12 patients for each cohort and study the PK profile of both drugs. The 12 patients in each cohort will be sequentially alternated to group 1 or group 2 treatment schedules. Group 1 N6 patients in each cohort will receive vinorelbine three times per week starting on Monday Day 1 followed by Wednesday Day 3 and Friday Day 5. In the subsequent weeks vinorelbine will be given on the same working days i.e. Monday, Wednesday and Friday. The first PK profile of vinorelbine without concomitant sorafenib will be determined on Day 15 under steady state conditions. 